Testing Warning Labels for Retail Cannabis Products Using a Discrete Choice Experiment
24. Juli 2026 aktualisiert von: University of Oklahoma
Developing and Testing Warning Labels for Retail Cannabis Products
This discrete choice experiment (DCE) study aims to address gaps in cannabis packaging regulatory research by testing how variations in cannabis packaging and health warning design impact reactions to packaging and intentions about cannabis use.
The goal of this work is to identify the most effective combination of health warning features to improve consumer awareness of cannabis health risks.
Establishing criteria for cannabis products in the US is critical because inconsistent state guidelines have resulted in contradictory policies in legal retail states, arguably leading to increased hazardous use and failure to meet public health standards.
The contributions of this study's outcomes are expected to be significant because they will benefit public health as cannabis becomes available in legal retail markets and regulatory and governmental agencies seek effective ways to communicate cannabis risks to the public.
Studienübersicht
Status
Rekrutierung
Bedingungen
Intervention / Behandlung
Detaillierte Beschreibung
The DCE will be conducted via a self-administered online questionnaire, with inclusion criteria assessed before assignment to choice set conditions.
Participants will be residents of legal-retail cannabis use states, able to legally purchase cannabis (21 or older), who have used cannabis in the past 30 days (i.e., current use).
Frequency of cannabis use (i.e., monthly, weekly, daily), mode (e.g., flower, vape, etc.), and dose (i.e., THC level) will be measured through self-report.
Inclusion criteria are reported using cannabis (any mode) in the past 30 days.
Consented participants will be presented with descriptions of cannabis packaging attributes and an example choice set to become familiar with DCE tasks.
Participants will be asked to imagine the cannabis products in the DCE as the only choices they have available to them "in the near future" and to evaluate images within this scenario.
Participants will be randomly assigned to view 16 choice sets.
To optimize the evaluation of preferences and reduce respondent burden, we will assign contrasting labels to "choice sets," each of which will include 4 images of products in such a way that each attribute level appears an equal number of times in combination with all other attribute levels.
Presentation order of the 16 choice sets will be randomized within and across choice sets to minimize ordering effects.
Participants will view each choice set for as long as they wish.
After evaluating choice sets, participants will complete a recall task to assess retention of health warning information and will be provided a debrief page with information about substance use and resources for seeking help with substance use.
Studientyp
Interventionell
Einschreibung (Geschätzt)
450
Phase
- Unzutreffend
Kontakte und Standorte
Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.
Studienkontakt
- Name: Zachary Massey, PhD
- Telefonnummer: 405-271-6872
- E-Mail: zachary-massey@ou.edu
Studienorte
-
-
Oklahoma
-
Oklahoma City, Oklahoma, Vereinigte Staaten, 73104
- Rekrutierung
- University of Oklahoma
-
Kontakt:
- Zachary Massey, PhD
- Telefonnummer: 405-271-6872
- E-Mail: zachary-massey@ou.edu
-
-
Teilnahmekriterien
Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.
Zulassungskriterien
Studienberechtigtes Alter
- Erwachsene
- Älterer Erwachsener
Akzeptiert gesunde Freiwillige
Nein
Studienpopulation
The study population consists of adults aged 21 years and older residing in U.S. states with legal retail cannabis markets (i.e., adult use non-medical or "recreational") who report cannabis use within the past 30 days.
Participants will be recruited from an online consumer research panel and will represent active adult cannabis consumers in these jurisdictions.
Beschreibung
Eligibility for participation includes: 1) being 21 years of age or older, 2) being able to speak and understand English, 3) self-reported having consumed cannabis in the last 30 days (any mode, e.g., flower, vape, edible, etc.), and 4) residing in a U.S. state or jurisdiction where retail (i.e., non-medical) cannabis use is legal.
Studienplan
Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Verhütung
- Zuteilung: N / A
- Interventionsmodell: Einzelgruppenzuweisung
- Maskierung: Keine (Offenes Etikett)
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
|---|---|
|
Experimental: Discrete choice experiment (DCE) cohort
Adult participants (21+) enrolled in this single-arm cohort will complete a computer-based discrete choice experiment during a single study visit (conducted online).
They will review a series of hypothetical cannabis products and select their preferred options.
|
A discrete choice experiment (DCE) consisting of 16 distinct choice sets.
Each choice set presents combinations of the following attributes: 1) Cannabis package style: 1) "Standardized" plain package, 2) plain package with brand logo and fonts, 3) brand color background with brand logo and fonts, and 4) fully branded with brand imagery, brand logo, and brand descriptors and fonts.
Branding type: 1) Adventure brand vs. 2) Earthy brand.
Health warning size: 1) Small (20% of packaging surface) - health warnings use currently mandated warning language from multiple jurisdictions vs. 2) Large (40% of packaging surface) - health warnings use currently mandated warning language from multiple jurisdictions.
Product THC content: 1) Low THC vs. 2) High THC.
Product type: 1) Joints, 2) Vape, 3) Edibles, and 4) Drinks.
Participants will rate all combinations of product attributes.
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Risk perceptions about cannabis products
Zeitfenster: At the time of survey completion (approximately 15 minutes)
|
Binary measure using best-worst scaling.
For each question, participants will also have the option of indicating none of the above/opt-out as a response.
For each choice set, the statement selected as the best option will be coded using a value of 1, and the worst will be coded as -1.
The remaining statements in that set will be coded as 0. If the participant selects none of the above, all statements in that choice set will be assigned a value of 0.
|
At the time of survey completion (approximately 15 minutes)
|
|
Cannabis product use intentions
Zeitfenster: At the time of survey completion (approximately 15 minutes)
|
Binary measure using best-worst scaling.
For each question, participants will also have the option of indicating none of the above/opt-out as a response.
For each choice set, the statement selected as the best option will be coded using a value of 1, and the worst will be coded as -1.
The remaining statements in that set will be coded as 0. If the participant selects none of the above, all statements in that choice set will be assigned a value of 0.
|
At the time of survey completion (approximately 15 minutes)
|
Mitarbeiter und Ermittler
Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.
Sponsor
Mitarbeiter
Ermittler
- Hauptermittler: Zachary Massey, PhD, University of Oklahoma
Studienaufzeichnungsdaten
Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.
Haupttermine studieren
Studienbeginn (Tatsächlich)
19. Mai 2026
Primärer Abschluss (Geschätzt)
31. Dezember 2026
Studienabschluss (Geschätzt)
31. Dezember 2026
Studienanmeldedaten
Zuerst eingereicht
7. Juli 2026
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
7. Juli 2026
Zuerst gepostet (Tatsächlich)
14. Juli 2026
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
27. Juli 2026
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
24. Juli 2026
Zuletzt verifiziert
1. Juli 2026
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
- 17276
- 1K01DA057395-01A1 (US NIH Stipendium/Vertrag)
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
UNENTSCHIEDEN
Beschreibung des IPD-Plans
The data that support the findings of this study are available from the corresponding author upon reasonable request.
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Nein
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Nein
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .